Urology

Top Medical News
2 days ago
Meatal correction shows limited efficacy in young girls with anterior-deflected urinary stream (ADUS) and daytime urinary incontinence (DUI), a new study has found.
Stephen Padilla, 3 days ago
Treatment with apalutamide plus androgen deprivation therapy (ADT) results in consistently favourable pain scores and less interference from pain in the daily lives of patients with metastatic castration-sensitive prostate cancer compared with placebo plus ADT, results of the phase III TITAN study have shown. Moreover, there was no difference for change seen in fatigue with apalutamide vs placebo.
Audrey Abella, 3 days ago
The use of pembrolizumab significantly improved disease-free survival (DFS) in patients with clear-cell renal cell carcinoma (RCC) who have undergone nephrectomy, with or without metastasectomy, and were at high risk for recurrence, according to the phase III KEYNOTE-564 trial.
5 days ago
There seems to be an increasing trend in the diagnosis rate of benign prostatic hyperplasia (BPH), accompanied by a gradual rise in medical treatment and decline in surgical interventions, a new South Korea study has shown.
09 Sep 2021
A recent study suggests the utilization of urine colour alone and the combination of urine colour (UC) with void number as a simple field-measure to identify underhydration in adults and children based on elevated urine osmolality (UOsm).
Roshini Claire Anthony, 08 Sep 2021

The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.

Roshini Claire Anthony, 07 Sep 2021

The benefits of active surveillance for prostate cancer appear to be greater in men diagnosed with low-risk prostate cancer at an older age, according to a study from Sweden.

Special Reports
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
Conference Reports
Roshini Claire Anthony, 08 Sep 2021

The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.

Roshini Claire Anthony, 07 Sep 2021

The benefits of active surveillance for prostate cancer appear to be greater in men diagnosed with low-risk prostate cancer at an older age, according to a study from Sweden.

Elvira Manzano, 07 Sep 2021
An MRI-targeted biopsy* plus a new risk score cuts unnecessary biopsies by half in men with positive MRI results and elevated PSA** levels in the STHLM3-MRI study. This benefit comes without missing clinically significant cancers, experts report at EAU 2021.
Roshini Claire Anthony, 26 Aug 2021

High levels of cotinine in the urine of smokers who have undergone resection for non-muscle invasive bladder cancer (NMIBC) could be a sign of cancer recurrence, according to a study from Lebanon presented at EAU21.

Audrey Abella, 20 Aug 2021
In individuals with neurogenic detrusor overactivity incontinence (NDOI) who were regularly undergoing clean intermittent catheterization, significant reductions of urinary incontinence episodes were seen following treatment with abobotulinumtoxinA (aboBoNT-A), according to a pooled analysis of two CONTENT studies presented at EAU 2021.
Audrey Abella, 19 Aug 2021
In a systematic review and meta-analysis of randomized controlled trials (RCTs) presented at EAU 2021, the use of botulinum toxin (BTX) type A in individuals with neurogenic detrusor overactivity (NDO) and idiopathic overactive bladder (iOAB) led to a reduction in incontinence episodes.
Elaine Soliven, 18 Aug 2021
The sublingual bacterial vaccine MV140 reduces the number of recurrent urinary tract infections (UTIs) in women, according to a European study presented at EAU21.